Treatment / Procedure

Red Light Therapy and Photobiomodulation

A comprehensive guide explaining the current evidence up to 2026, dose parameters, and safety of red light therapy and photobiomodulation across skin, hair, pain, wound, recovery, and emerging areas of use.

Written by: Dr. Kerem Çağlayan Medically reviewed by: Dr. Kerem Çağlayan First published: September 9, 2026 Last updated: September 28, 2026 Last medical review: September 27, 2026

Short answerRed Light therapy / photobiomodulation (PBM) is a non-invasive method that utilizes the interaction of red and near-infrared light with biological tissue at controlled wavelengths and doses. The scientific literature demonstrates the strongest and most consistent signals in androgenetic alopecia, certain areas of wound and tissue repair, some pain conditions, and specific dermatological indications. There are also human studies in areas such as skin rejuvenation, exercise recovery, sleep, and cognitive performance; however, the certainty and applicability of the findings vary depending on the indication.

Why is there no “single Red Light treatment”?

In PBM, the outcome is influenced not only by the color of the light, but also by wavelength, irradiance (mW/cm²), energy density (J/cm²), total treatment area, distance, duration, session frequency, whether the light source is LED or laser, and the depth of the target tissue. Very different devices and protocols can exist under the same name of “red light.” For this reason, it is not accurate to deduce clinical efficacy solely based on wattage, number of LEDs, or the brightness of the device.

In red light applications, wavelengths around approximately 630–660 nm are frequently investigated, while in near-infrared applications, wavelengths around approximately 810–850 nm are commonly studied. These are not fixed values in the nature of a prescription; the clinical protocol varies depending on the target tissue and device characteristics.

How is it thought to work?

The biological effect of PBM cannot be reduced to a single mechanism. The primary pathways investigated include mitochondrial chromophores and cytochrome c oxidase, cellular redox signaling, ATP production, nitric oxide bioavailability, inflammation-related signaling pathways, and tissue repair processes. Clinical effect may vary depending on the target tissue, baseline status, and dose parameters. Higher energy does not always mean a stronger outcome; the biphasic dose response is an important concept in the PBM literature.

What does the scientific evidence say as of 2026?

Area	Overview of the evidence	Clinical commentary
Androgenetic alopecia	Meta-analyses and randomized trials show a positive hair density signal.	One of the best-studied areas of PBM; the type of hair loss must be accurately identified.
Skin rejuvenation	Randomized trials report some positive outcomes in fine lines and photographic measurements.	A supportive non-invasive option; does not replace treatment for significant sagging or volume loss.
Pain / musculoskeletal	There are positive results in some conditions; protocols and diagnoses are heterogeneous.	Should be evaluated diagnosis-specifically and as part of a multimodal plan.
Wound and tissue repair	Strong clinical signals exist in certain wound types and acute radiation dermatitis.	As a supportive measure in selected cases, not as a replacement for standard wound care.
Exercise and recovery	Although there are positive signals in systematic reviews, protocol heterogeneity is high.	Does not replace sleep, nutrition, and training management.
Sleep / cognition	There are new randomized trials and meta-analyses; the field is still emerging.	Should be viewed within an investigational/individual evaluation framework, not as routine standard treatment.

The big picture: What did 204 randomized trials show?

A 2025 umbrella review evaluated 204 randomized controlled trials across 15 meta-analyses and more than 9,000 participants. A significant effect was identified in 12 of the 35 clinical outcomes examined. Moderate-certainty evidence was reported for certain outcomes such as hair density in androgenetic alopecia, functional disability in knee osteoarthritis, fatigue in fibromyalgia, pain in burning mouth syndrome, and cognitive function. However, the certainty of evidence for many other outcomes was low or very low, and publication bias/study heterogeneity were among the major limitations.

For this reason, rather than viewing PBM as “red light that is good for every problem,” it is more accurate to approach it as a technology whose evidence must be evaluated separately specific to each indication and protocol.

Skin rejuvenation, fine lines, and collagen

In skin aging, PBM is investigated through fibroblast activity, cellular energy metabolism, and tissue repair signaling. A 2024 dermatology review, while summarizing the dermatological uses and mechanisms of red and near-infrared PBM, emphasized that protocol standardization remains an important need.

In a randomized, sham-controlled, double-blind study published in 2025, 95 women aged 45–60 were evaluated. While no significant difference was observed between groups in the experts’ Wrinkle Assessment Scale evaluation, computerized image analysis reported a significant reduction in glabellar and right periorbital wrinkle length in the PBM groups, as well as an increase in participant satisfaction compared to the sham group. The lack of distinct superiority between two and three sessions/week supports that the assumption “more frequent application is always better” may not be correct.

In another split-face randomized study, 660 nm red light and 590 nm amber light protocols were compared for periocular wrinkles, and clinical signals in favor of red light were reported. Although these studies are promising, outcomes depend on the device, dose, and patient population.

Detailed content: Red Light and Skin Rejuvenation →

Hair loss and androgenetic alopecia

Hair loss is one of the better-studied areas of PBM. A 2025 systematic review and meta-analysis evaluated a total of 3,098 individuals across 38 studies; the vast majority of participants had androgenetic alopecia. Compared with placebo, a significant increase in hair density was reported. However, heterogeneity was high, and data were much more limited for other hair loss types such as telogen effluvium, alopecia areata, or cicatricial alopecia.

For this reason, before applying Red Light to the scalp, it should be evaluated whether the hair loss is androgenetic, telogen, related to an iron/thyroid/nutritional cause, or whether a scalp disease is present.

Detailed content: Red Light and Hair Loss →

Pain, osteoarthritis, and the musculoskeletal system

The analgesic and functional effects of PBM have long been investigated. The 2025 umbrella review reported moderate-certainty favorable outcomes for functional disability in knee osteoarthritis and fatigue in fibromyalgia. A systematic review of chronic pain randomized trials published in 2026 also compiled PBM studies across different chronic pain presentations; however, marked differences in clinical diagnosis, wavelength, dose, and treatment regimens make it difficult to recommend a single protocol for all chronic pain patients.

In our Bodrum clinic, we do not use PBM as a substitute for pain diagnosis. First, the source of pain, neurological findings, joint/tendon pathology, and physical capacity are evaluated; in appropriate individuals, it can be planned as an adjunct to exercise, rehabilitation, and other treatments.

Detailed content: Red Light and Pain →

Wounds, scars, and tissue repair

A 2025 international consensus reported evidence favoring clinical benefit for PBM in areas such as peripheral neuropathy, androgenetic alopecia, wound ulcers of various etiologies, decubitus ulcers, diabetic foot ulcer-related pain, and acute radiation dermatitis. In chronic wound management, however, PBM never replaces circulatory evaluation, infection control, glucose management, pressure offloading, debridement, and appropriate dressing.

A 2026 review of scar literature identified only seven prospective/randomized studies and a total of 297 participants for red and near-infrared PBM; although results were promising, the studies were small and heterogeneous. Larger standardized studies are needed in this field.

Exercise performance and recovery

A 2025 systematic review evaluated studies on whole-body PBM and exercise performance/recovery. While some studies reported benefit signals in performance or recovery indicators, outcomes cannot be reduced to a single protocol due to differences in device, application timing, muscle group, and dose. In athletic use, PBM should be considered a potential complement, rather than a replacement for sleep, protein/energy adequacy, load management, and active recovery.

Sleep and cognitive performance: a promising but evolving field

In a 2025 meta-analysis of randomized trials, positive signals of transcranial PBM on cognitive function were reported. A sleep meta-analysis published in 2026 included five randomized trials and 240 participants; a small improvement in the Pittsburgh Sleep Quality Index score compared to sham controls was reported, but confidence intervals were wide. For this reason, while the field of sleep and cognition is clinically interesting, it is not yet as established an area of use as dermatology or androgenetic alopecia.

Safety: what do we know?

In the 2025 JAAD consensus, PBM was evaluated as a generally safe modality in adults, and it was noted that there is no evidence that red light PBM causes DNA damage. The most common practical issues are eye safety, heat generated by the device, photosensitizing medications, active skin diseases, and unexplained lesions in the application area.

A 2023 systematic review on oncologic safety found no clinical data showing an association between low-level red/near-infrared light for aesthetic skin rejuvenation and new or recurrent malignancy. However, rather than “assuming it is safe and applying it” over an active or suspicious lesion, a medical evaluation must be performed first.

Appropriate eye protection for the device and wavelength must be used around the eyes.
Photosensitizing medications and conditions should be inquired about.
New, rapidly growing, bleeding, or unexplained skin lesions must be evaluated first.
PBM should not be substituted for proven diagnoses and treatments.

Our approach at our Bodrum clinic

We do not apply photobiomodulation as “the same duration of red light for everyone.” First, we determine the target tissue and the clinical objective. Protocols used for hair, skin, the musculoskeletal system, wounds, or recovery purposes are not the same.

In planning, as much as possible, we keep wavelength, irradiance, energy density, application distance, duration, and session frequency measurable. Baseline status can be recorded depending on the target using photographs, hair density, pain/function scores, range of motion, or other objective measurements. If adequate benefit is not observed during serial follow-up, the protocol or the role of PBM in the treatment plan is reevaluated.

Are Red Light and infrared sauna the same thing?

No. In photobiomodulation, the goal is to generate a photochemical and cellular signaling response at specific wavelengths. In an infrared sauna, the primary biological stimulus is heat and the thermal response. Although the term “infrared” may appear in both, the physics of application and the targeted biological effect are not the same.

Selected scientific references

Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: September 27, 2026
Disclaimer: This content is for general medical information purposes only; it does not substitute for personal diagnosis or treatment recommendations.

Clinical evaluation in Bodrum: You can use the Bodrum Clinic and Appointment & Contact pages to discuss whether the treatment is suitable for you.

Medical editorial information

This content has been medically reviewed and approved by Dr. Kerem Çağlayan. It is intended for general education and does not replace an individual diagnosis or treatment plan.